Generic Name: semaglutide
Brand Name: TBC
Manufacturer: Novo Nordisk Canada Inc.
Indications: diabetes mellitus, type 2
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with type 2 diabetes mellitus to improve glycemic control, in combination with metformin (second line treatment) and in combination with metformin and sulfonylurea (third line treatment).
Submission Type: New
Project Status: Pending
Call For Patient Input: October 24, 2019
Patient Input Closed: December 12, 2019
Fee Schedule: Pending
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.